10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
IPO Year: 2019
Exchange: NASDAQ
Website: 10xgenomics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/18/2024 | $40.00 → $20.00 | Overweight → Neutral | JP Morgan |
7/10/2024 | $55.00 → $25.00 | Buy → Hold | Deutsche Bank |
6/27/2024 | Outperform → Peer Perform | Wolfe Research | |
6/25/2024 | Buy → Neutral | Guggenheim | |
6/3/2024 | $24.00 | Hold | Jefferies |
5/1/2024 | $57.00 → $32.00 | Buy → Hold | TD Cowen |
12/14/2023 | $60.00 | Buy | Guggenheim |
12/13/2023 | $55.00 | Outperform | Wolfe Research |
12/12/2023 | $36.00 → $54.00 | Underperform → Neutral | BofA Securities |
7/5/2023 | $65.00 | Overweight | JP Morgan |
Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an
Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar
JP Morgan downgraded 10x Genomics from Overweight to Neutral and set a new price target of $20.00 from $40.00 previously
Deutsche Bank downgraded 10x Genomics from Buy to Hold and set a new price target of $25.00 from $55.00 previously
Wolfe Research downgraded 10x Genomics from Outperform to Peer Perform
Guggenheim downgraded 10x Genomics from Buy to Neutral
Jefferies resumed coverage of 10x Genomics with a rating of Hold and set a new price target of $24.00
TD Cowen downgraded 10x Genomics from Buy to Hold and set a new price target of $32.00 from $57.00 previously
Guggenheim initiated coverage of 10x Genomics with a rating of Buy and set a new price target of $60.00
Wolfe Research initiated coverage of 10x Genomics with a rating of Outperform and set a new price target of $55.00
BofA Securities upgraded 10x Genomics from Underperform to Neutral and set a new price target of $54.00 from $36.00 previously
JP Morgan resumed coverage of 10x Genomics with a rating of Overweight and set a new price target of $65.00
3 - 10x Genomics, Inc. (0001770787) (Issuer)
3 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
8-K - 10x Genomics, Inc. (0001770787) (Filer)
8-K - 10x Genomics, Inc. (0001770787) (Filer)
8-K - 10x Genomics, Inc. (0001770787) (Filer)
DEFA14A - 10x Genomics, Inc. (0001770787) (Filer)
10-Q - 10x Genomics, Inc. (0001770787) (Filer)
8-K - 10x Genomics, Inc. (0001770787) (Filer)
DEFA14A - 10x Genomics, Inc. (0001770787) (Filer)
DEF 14A - 10x Genomics, Inc. (0001770787) (Filer)
PRE 14A - 10x Genomics, Inc. (0001770787) (Filer)
S-8 - 10x Genomics, Inc. (0001770787) (Filer)
PLEASANTON, Calif., July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the second quarter ended June 30, 2024 after market close on Thursday, August 8, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
Researchers used Chromium Single Cell products and Xenium In Situ to profile how gene expression is spatially regulated during secondary palate formation PLEASANTON, Calif., June 27, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that its Xenium In Situ platform was used in a study published in the Journal of Dental Research, offering novel insights into cellular mechanisms regulating the formation of the secondary palate. The study was led by researchers at the National Institutes of Health (NIH) in collaboration with computational experts at the University of Connecticut's Schools of Medicine and Dental Medicine.
New 5,000-plex gene panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif., June 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that it has started shipping its new Xenium Prime 5K Pan-Tissue and Pathways panel. The new panel features an enhanced chemistry to increase plex by an order of magnitude while delivering excellent per-gene sensitivity, improved specificity and spatial fidelity, integrated multimodal cell segmentation and industry-leading speed and throughput.
New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif., May 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel. The new assay features an enhanced chemistry to increase plex by an order of magnitude while delivering excellent per-gene sensitivity, improved specificity and spatial fidelity, integrated multimodal cell segmentation, and industry-leading speed and throughput.
PLEASANTON, Calif., May 2, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, at 4:20 p.m. Pacific Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event. About 10x Genomics 10x
Court finds non-infringement by Curio Seeker with respect to over-reaching claim by 10x Genomics Curio Bioscience, a leading innovator of high-precision tools for the life sciences industry, today announced that a decision in a court case has been made. The European Unified Patent Court (UPC) today announced a finding that Curio Seeker does not infringe main claim 1 of EP 2697391 asserted by 10x Genomics (NASDAQ:TXG). The UPC has also ordered Curio Bioscience not to offer any product that would violate claim 14 of the ‘391 patent in France, Germany, and Sweden. Accordingly, Curio Bioscience will comply with the order and expects no impact to its commercial business. This ruling is res
PLEASANTON, Calif., April 30, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Revenue was $141.0 million for the first quarter, a 5% increase over the corresponding period of 2023, driven by Spatial revenue.Shipped Visium HD Spatial Gene Expression, enabling whole transcriptome spatial discovery at single cell-scale resolution.Shipped two major new Chromium products powered by GEM-X, the next generation of the company's leading singl
PLEASANTON, Calif., April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on Tuesday, April 30, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
Began global shipments for Visium HD, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution PLEASANTON, Calif., March 26, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product. This assay enables researchers to measure the whole transcriptome from FFPE tissue sections at single cell-scale resolution. "Visium HD is a game-changer for spatial discovery research, and our team couldn't be more proud an
Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue types PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications. These new products expand the breadth of the Xenium single cell spatial analysis menu.
PLEASANTON, Calif., July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the second quarter ended June 30, 2024 after market close on Thursday, August 8, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
PLEASANTON, Calif., April 30, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Revenue was $141.0 million for the first quarter, a 5% increase over the corresponding period of 2023, driven by Spatial revenue.Shipped Visium HD Spatial Gene Expression, enabling whole transcriptome spatial discovery at single cell-scale resolution.Shipped two major new Chromium products powered by GEM-X, the next generation of the company's leading singl
PLEASANTON, Calif., April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on Tuesday, April 30, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over the corresponding periods of 2022 PLEASANTON, Calif., Feb. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided outlook for 2024. Recent Highlights Revenue was $184.0 million for the fourth quarter and $618.7 million for the full year of 2023, representing 18% and 20% increases over the corresponding periods of 2022.Increased cumulative instruments sold t
PLEASANTON, Calif., Jan. 24, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after market close on Thursday, February 15, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
PLEASANTON, Calif., Oct. 11, 2023 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today it will report financial results for the third quarter 2023 after market close on Thursday, November 2, 2023. The company will host a conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call. Live
PLEASANTON, Calif., Aug. 3, 2023 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights Revenue was $146.8 million for the second quarter, representing a 28% increase over the corresponding period of 2022.Accelerated Xenium's momentum with strong shipments, multiple new curated and customizable gene panels and a major update of its onboard software to deliver even higher levels of performance.Launched the Visium CytAssist Gene and Protein Expres
PLEASANTON, Calif., July 13, 2023 /PRNewswire/ -- 10x Genomics (NASDAQ:TXG), a leader in single cell and spatial biology, announced today it will report financial results for the second quarter 2023 after market close on Thursday, August 3, 2023. The company will host a conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call. Live audio o
PLEASANTON, Calif., May 3, 2023 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG) today reported financial results for the first quarter ended March 31, 2023. Recent Highlights Revenue was $134.3 million for the first quarter, representing a 17% increase over the corresponding period of 2022.Surpassed 5,000 customer publications using 10x Genomics products, demonstrating the impact of single cell and spatial technologies to fuel new biological discoveries.Accelerated Spatial revenue growth driven by robust demand for Xenium in its first full quarter of commercial launch and cont
PLEASANTON, Calif., April 12, 2023 /PRNewswire/ -- 10x Genomics (NASDAQ:TXG), a life sciences leader focused on mastering biology to advance human health, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023. The company will host a conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
On Thursday, Cathie Wood’s Ark Invest made a significant move by reducing its stake in Tesla Inc (NASDAQ:TSLA), despite a recent bullish outlook on the company’s potential in the autonomous taxi sector. The Tesla Trade The ARK Next Generation Internet ETF (NYSE:ARKW) sold 32,199 shares of Tesla, valued at approximately $8.02 million based on the closing price of $249.23 on the same day. This move comes after recent comments by Wood, who expressed her belief that Tesla’s stock could see a significant surge as it moves into the autonomous taxi business. Wood, in a recent Tiger Money podcast, stated that Tesla could potentially capture up to 50% of the autonomous taxi market, presentin
B of A Securities analyst Derik De Bruin maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $36 to $25.
JP Morgan analyst Rachel Vatnsdal downgrades 10x Genomics (NASDAQ:TXG) from Overweight to Neutral and lowers the price target from $40 to $20.
In the preceding three months, 12 analysts have released ratings for 10x Genomics (NASDAQ:TXG), presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 5 0 2 Last 30D 1 0 0 0 0 1M Ago 0 1 1 0 1 2M Ago 0 0 1 0 0 3M Ago 3 0 3 0 1 Analysts have set 12-month price targets for 10x Genomics, revealing an average target of $33.0, a high estimate of $55.00, and a low estimate of $16.00. Observing a downward trend, the current
Stifel analyst Daniel Arias maintains 10x Genomics (NASDAQ:TXG) with a Buy and lowers the price target from $53 to $25.
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company’s flagship fund, ARK Innovation ETF (NYSE:ARKK), despite its recent underperformance. What Happened: Wood, in her letter, acknowledged that ARKK’s performance has been impacted by the shift in focus from the “Magnificent Six” to multiomics stocks, which have been adversely affected by the prospect of prolonged high interest rates. Despite this, ARKK’s valuation has dropped to a level that Wood believes is indicative of “deep value territory” over a five-year investment horizon. Wood pointed out that ARKK’s valuation, as of June, was 25.5x, the lowest it has been since Febru
Wednesday, Illumina Inc (NASDAQ:ILMN) acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research for an undisclosed consideration. Amid this M&A deal, 10x Genomics, Inc (NASDAQ:TXG) shares are trading lower. William Blair writes that Fluent’s PIPseq single-cell technology does not require an instrument, and costs per cell is at least 50% less than 10x and is the cheapest on the market, citing a recent bioRxiv preprint. William Blair highlights that cost reduction has become crucial in the increasingly crowded single-cell market. Bundled offerings will further strengthen Fluent’s competitive edge with low-cost positioning. While Illumina emphasize
Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) fell sharply during Wednesday's session after the company entered into a $10 million registered direct offering of 947,868 shares at $10.55 per share. SeaStar Medical shares dipped 34% to $8.55 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) shares jumped 139% to $2.78 after the company announced results for a Swine Model pilot study for Probudur. Kazia Therapeutics Limited (NASDAQ:KZIA) gained 129% to $0.4325 after the company announced results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of